1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pneumococcal Vaccines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pneumococcal Vaccines Market Revenue and Volume, by Vaccine Type
8.1.1 Pneumococcal Conjugate Vaccine
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Pneumococcal Polysaccharide Vaccine
8.1.2.1. Market Revenue and Volume Forecast
9.1. Pneumococcal Vaccines Market Revenue and Volume, by Product
9.1.1. Prevnar 13
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Synflorix
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Pneumovax 23
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. VAXNEUVANCE
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. PNEUMOSIL
9.1.5.1. Market Revenue and Volume Forecast
9.1.6. Other Products
9.1.6.1. Market Revenue and Volume Forecast
10.1. Pneumococcal Vaccines Market Revenue and Volume, by End-use
10.1.1. Public Sector
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Private Sector
10.1.2.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Vaccine Type
11.1.2. Market Revenue and Volume Forecast, by Product
11.1.3. Market Revenue and Volume Forecast, by End-use
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Vaccine Type
11.1.4.2. Market Revenue and Volume Forecast, by Product
11.1.4.3. Market Revenue and Volume Forecast, by End-use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Vaccine Type
11.1.5.2. Market Revenue and Volume Forecast, by Product
11.1.5.3. Market Revenue and Volume Forecast, by End-use
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Vaccine Type
11.2.2. Market Revenue and Volume Forecast, by Product
11.2.3. Market Revenue and Volume Forecast, by End-use
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Vaccine Type
11.2.4.2. Market Revenue and Volume Forecast, by Product
11.2.4.3. Market Revenue and Volume Forecast, by End-use
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Vaccine Type
11.2.5.2. Market Revenue and Volume Forecast, by Product
11.2.5.3. Market Revenue and Volume Forecast, by End-use
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Vaccine Type
11.2.6.2. Market Revenue and Volume Forecast, by Product
11.2.6.3. Market Revenue and Volume Forecast, by End-use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Vaccine Type
11.2.7.2. Market Revenue and Volume Forecast, by Product
11.2.7.3. Market Revenue and Volume Forecast, by End-use
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Vaccine Type
11.3.2. Market Revenue and Volume Forecast, by Product
11.3.3. Market Revenue and Volume Forecast, by End-use
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Vaccine Type
11.3.4.2. Market Revenue and Volume Forecast, by Product
11.3.4.3. Market Revenue and Volume Forecast, by End-use
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Vaccine Type
11.3.5.2. Market Revenue and Volume Forecast, by Product
11.3.5.3. Market Revenue and Volume Forecast, by End-use
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Vaccine Type
11.3.6.2. Market Revenue and Volume Forecast, by Product
11.3.6.3. Market Revenue and Volume Forecast, by End-use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Vaccine Type
11.3.7.2. Market Revenue and Volume Forecast, by Product
11.3.7.3. Market Revenue and Volume Forecast, by End-use
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Vaccine Type
11.4.2. Market Revenue and Volume Forecast, by Product
11.4.3. Market Revenue and Volume Forecast, by End-use
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Vaccine Type
11.4.4.2. Market Revenue and Volume Forecast, by Product
11.4.4.3. Market Revenue and Volume Forecast, by End-use
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Vaccine Type
11.4.5.2. Market Revenue and Volume Forecast, by Product
11.4.5.3. Market Revenue and Volume Forecast, by End-use
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Vaccine Type
11.4.6.2. Market Revenue and Volume Forecast, by Product
11.4.6.3. Market Revenue and Volume Forecast, by End-use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Vaccine Type
11.4.7.2. Market Revenue and Volume Forecast, by Product
11.4.7.3. Market Revenue and Volume Forecast, by End-use
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Vaccine Type
11.5.2. Market Revenue and Volume Forecast, by Product
11.5.3. Market Revenue and Volume Forecast, by End-use
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Vaccine Type
11.5.4.2. Market Revenue and Volume Forecast, by Product
11.5.4.3. Market Revenue and Volume Forecast, by End-use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Vaccine Type
11.5.5.2. Market Revenue and Volume Forecast, by Product
11.5.5.3. Market Revenue and Volume Forecast, by End-use
12.1. Serum Institute of India Pvt. Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. CSL
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sanofi
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GSK plc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Merck & Co., Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Walvax Biotechnology Co., Ltd
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Beijing Minhai Biotechnology Co., Ltd
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. China National Biotec Group
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sinovac Biotech Ltd
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
